您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > (-)-p-Bromotetramisole Oxalate
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
(-)-p-Bromotetramisole Oxalate
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
(-)-p-Bromotetramisole Oxalate图片
CAS NO:62284-79-1
规格:≥98%
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)373.22
FormulaC13H13BrN2O4S
CAS No.62284-79-1
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 74 mg/mL (198.3 mM)
Water: 30 mg/mL (80.4 mM)
Ethanol: <1 mg/mL
Other info

Chemical Name: (S)-6-(4-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole oxalate

InChi Key: ZULBIBHDIQCNIS-HNCPQSOCSA-N

InChi Code: InChI=1S/C11H11BrN2S.C2H2O4/c12-9-3-1-8(2-4-9)10-7-14-5-6-15-11(14)13-10;3-1(4)2(5)6/h1-4,10H,5-7H2;(H,3,4)(H,5,6)/t10-;/m1./s1

SMILES Code: BrC1=CC=C([C@H]2CN3C(SCC3)=N2)C=C1.OC(C(O)=O)=O

SynonymsL-p-Bromotetramisole oxalate; 6-Bromolevamisole oxalate; (-)-p-Bromolevamisole oxalate; L-p-Bromotetramisole Oxalate
实验参考方法
In Vitro

In vitro activity: (-)-p-Bromotetramisole Oxalate is an inhibitor of alkaline phosphatase and protein tyrosine phosphatases. In various rat tissues, (-)-p-Bromotetramisole Oxalate (0.1 μM) completely inhibited non-specific alkaline phosphatase. In rat zona glomerulosa, (-)-p-Bromotetramisole Oxalate (100 μM) blocked the inhibition of Na+ pump (Na+, K+-ATPase) induced by angiotensin II. The result suggested that inhibition of the Na+ pump induced by angiotensin II might be mediated by a tyrosine phosphatase. In neurosecretory PC12 cells, (-)-p-Bromotetramisole Oxalate (0.3 mM) increased ionomycin-stimulated noradrenaline (NA) release, which suggested that tyrosine phosphorylation regulated Ca2+-stimulated NA release.

In VivoIn Sprague-Dawley rats, (-)-p-Bromotetramisole Oxalate (10 μM) significantly increased fractional excretion of phosphate (FEPi) from 4.7% to 13.4%.
Animal modelRats
Formulation & Dosage10 μM
References

Histochemistry, 1975, 44(3): 277-280; Eur J Pharmacol, 2000, 406(1): 49-52; Proc Soc Exp Biol Med, 1996, 213(2): 193-195.